美股A股
StockGist
Back
8-K2026-02-12· glm-5

QNCX · IRulya Therapeutics Inc.

0001193125-26-047544

SEC filing

Summary

Quince Therapeutics, Inc. reported preliminary cash and investments of $17.7 million as of December 31, 2025, against $16.4 million outstanding on its EIB Loan. The Company engaged LifeSci Capital to pursue strategic alternatives, primarily a reverse merger, following the failure of its lead drug candidate eDSP in the NEAT clinical trial.

Key takeaways